[1] WIERDA W G,BYRD J C,ABRAMSON J S,et al.Chronic lymphocytic leukemia/small lymphocytic lymphoma,version 4.2020,NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw,2020,18(2):185-217. [2] SZCZEPANEK E,et al.Long-term outcomes of imatinib real-life treatment for chronic myeloid leukemia-a 20-year review[J]. Blood,2020,136:52-53. [3] 袁婷,王晓燕,赖悦云,等. 慢性髓性白血病患者酪氨酸激酶抑制剂治疗中发生的Ph阴性髓系肿瘤[J]. 中华血液学杂志,2019,40(7):547-553. [4] CHEN Y L,YIN H,CHEN L F,et al.Feasibility study of switching to nilotinib after first-line imatinib in the chronic phase of chronic myeloid leukemia[J]. Clin Lymphoma Myeloma Leuk,2020,20(2):e43-e49. [5] 中华医学会血液学分会. 慢性髓性白血病中国诊断与治疗指南(2020年版)[J]. 中华血液学杂志,2020,41(5):353-364. [6] 王凯,刘涛,戴静,等. CML患者在TKI治疗过程中的细胞遗传学变化与病程演进的关系分析[J]. 中国实验血液学杂志,2020,28(1):136-140. [7] BRÜMMENDORF T H,GAMBACORTI-PASSERINI C,BUSHMAKIN A G,et al. Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia[J]. Ann Hematol,2020,99(6):1241-1249. [8] 陈怡琳,孟力,袁国林,等. 国产达沙替尼二线治疗慢性髓性白血病早期分子学反应的预后意义[J]. 中华血液学杂志,2019,40(7):608-611. [9] CORTES J E,GAMBACORTI-PASSERINI C,DEININGER M W,et al.Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia:results from the randomized BFORE trial[J]. J Clin Oncol,2018,36(3):231-237. [10] HOCHHAUS A,O'BRIEN S G,GUILHOT F,et al. Erratum:Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia[J]. Leukemia,2010,24(5):1102. [11] HOCHHAUS A,BACCARANI M,SILVER R T,et al.European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia[J]. Leukemia,2020,34(4):966-984. [12] OSMAN A E G,DEININGER M W. Chronic Myeloid Leukemia:modern therapies,current challenges and future directions[J]. Blood Rev,2021,49:100825. [13] 薛磊,杨会志,王兴兵,等. 尼洛替尼与伊马替尼治疗慢性粒细胞白血病早期临床疗效比较[J]. 安徽医学,2018,39(8):944-947. [14] 殷华,陈丽凤,崔杰克,等. 尼洛替尼和伊马替尼一线治疗初诊慢性髓性白血病慢性期的比较[J]. 中华内科杂志,2017,56(11):810-815. [15] MANZELLA L,TIRRÒ E,VITALE S R,et al.Optimal response in a patient with CML expressing BCR-ABL1 E6A2 fusion transcript with nilotinib therapy:a case report[J]. In Vivo,2020,34(3):1481-1486. [16] 石大雨,秦亚溱,赖悦云,等. BCR-ABL激酶区突变在酪氨酸激酶抑制剂耐药慢性髓性白血病患者中的分布及其影响因素[J]. 中华血液学杂志,2020,41(6):469-476. [17] 徐海萍,金涛. 达沙替尼治疗伴Y253F/H突变费城染色体阳性急性淋巴细胞白血病导致急性粒细胞缺乏1例[J]. 中国医药指南,2017,15(29):208-209. [18] 徐慧,王苹,马荣军,等. 尼洛替尼一线、二线治疗慢性髓性白血病慢性期分子学反应的对比研究[J]. 中华血液学杂志,2019,40(6):522-525. [19] 袁红建,孙善芳,钱小丽,等. 酪氨酸激酶抑制剂治疗慢性髓性白血病早期分子学反应的预后意义[J]. 吉林医学,2018,39(9):1707-1708. [20] 陈凌云,李珍,张龑莉,等. 尼洛替尼一线治疗慢性髓性白血病的疗效及影响实现分子学反应的因素分析[J]. 中华血液学杂志,2020,41(6):477-482. |